Inhibitory effect of traditional herbal (kampo) medicines on the replication of human parainfluenza virus type 2 in vitro

Jun Uematsu¹,*,§, Hidetaka Yamamoto², Sahoko Kihira³,a,§, Kae Sakai-Sugino³,b,§, Yuhko Ishiyama¹, Misaki Chindoh¹, Aya Baba¹, Rina Kazuta³, Tomomi Hasegawa³, Keiko Fujimoto¹, Aya Funachi³, Ai Itoh³, Ayumi Ookohchi³, Saemi Satoh³, Yurie Maeda³, Mitsuo Kawano⁴, Masato Tsurudome⁴, Miwako Nishio⁴, Kazuyuki Hirai¹, Myles O’Brien⁵, Hiroshi Komada¹,c

¹Microbiology and Immunology Section, Department of Clinical Nutrition, Graduate School of Health Science, Suzuka University of Medical Science, Suzuka, Mie, Japan; ²Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, Japan; ³Department of Clinical Nutrition, Faculty of Health Science, Suzuka University of Medical Science, Suzuka, Mie, Japan; ⁴Department of Microbiology, Mie University Graduate School of Medicine, Tsu, Mie, Japan; ⁵Graduate School of Mie Prefectural College of Nursing, Tsu, Mie, Japan.

SUMMARY

Thirteen herbal medicines, Kakkonto (TJ-001), Kakkontokasenkyushin'i (TJ-002), Hangekobokuto (TJ-016), Shoseiriyuto (TJ-019), Maoto (TJ-027), Bakumondoto (TJ-029), Hochuekkito (TJ-041), Goshakusan (TJ-063), Kososan (TJ-070), Chikujountanto (TJ-091), Gokoto (TJ-095), Saibokuto (TJ-096), and Ryokankyomishingeninto (TJ-119) were tested for human parainfluenza virus type 2 (hPIV-2) replication. Eight (TJ-001, TJ-002, TJ-019, TJ-029, TJ-041, TJ-063, TJ-095 and TJ-119) out of the thirteen medicines had virus growth inhibitory activity. TJ-001 and TJ-002 inhibited virus release, and largely inhibited genome, mRNA and protein syntheses. TJ-019 slightly inhibited virus release, gene and mRNA syntheses, and largely inhibited protein synthesis. TJ-029 slightly inhibited virus release, largely inhibited protein synthesis, but gene and mRNA syntheses were unaffected. TJ-041 only slightly inhibited virus release, gene and mRNA syntheses, but largely inhibited protein synthesis. TJ-091 largely inhibited gene, mRNA and protein syntheses. TJ-095 largely inhibited gene synthesis, but NP and HN mRNAs were slightly detected, and protein syntheses were observed. TJ-119 inhibited gene, mRNA and protein syntheses. TJ-001, TJ-002, TJ-091, TJ-095 and TJ-119 inhibited multinucleated giant cell formation derived from cell-to-cell spreading of virus. However, in TJ-019, TJ-029 and TJ-041 treated infected cells, only small sized fused cells with some nuclei were found. TJ-019 and TJ-041 slightly disrupted actin microfilaments, and TJ-001 and TJ-002 destroyed them. TJ-041 slightly disrupted microtubules, and TJ-001 and TJ-002 disrupted them. In general, the medicines effective on common cold and bronchitis inhibited hPIV-2 replication.

Keywords

virus replication, recombinant green fluorescence protein-expressing hPIV-2 without matrix protein, negative-strand RNA virus

1. Introduction

Human parainfluenza virus type 2 (hPIV-2) is one of the major human respiratory tract pathogens of infants and children. hPIV-2 is a member of the genus Rubulavirus in the family Paramyxoviridae, and it possesses a single-stranded, non-segmented, negative stranded RNA genome of 15,654 nucleotides (1). hPIV-2 has seven structural proteins, nucleoprotein (NP), the fifth (V), phospho (P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN) and large (L) proteins. The gene order of hPIV-2 is 3’-(leader)-NP-V/P-M-F-HN-L-(trailer)-5’. All genes of hPIV-2 were sequenced by our group (2-7). Monoclonal antibodies (mAbs) were made, and antigenic diversity of clinical isolates was investigated, by Tsurudome (8). The infectious hPIV-2 from cDNA clone was constructed by Kawano, and it was shown that its growth property was the same as that of control natural hPIV-2 (9).

Traditional herbal medicines have had an important role in Far East countries, especially in China, Korea and Japan for many years. Shoseiriyuto inhibited mouse
adapted influenza A/G/(H3N2) or B virus replication in nasal cavity and lung of ~6 month-old BALB/c mice after oral administration from 7 days to 4 days after infection, suggesting that it is useful for influenza virus infection in aged persons and protects against both subtypes A and B (10). Maoto has clinical and virological efficacy for influenza virus by inhibiting uncoating of influenza virus A (11). Hochuekkito also has protective effects against influenza virus, and it stimulates the upper respiratory mucosal immune system (12). However, there are no reports on the effect of traditional herbal medicines on human parainfluenza viruses. We here report the effects of traditional herbal medicines on the replication of hPIV-2.

In the present investigation, thirteen herbal medicines were tested for hPIV-2 growth, and it was found that eight had inhibitory effects on hPIV-2. To investigate the effects of the medicines on viral genome synthesis, virus RNA was prepared and analyzed by PCR and real-time PCR. To elucidate the effects of the eight drugs on mRNA synthesis, cDNA was synthesized using oligo(dT) primer and PCR was carried out. Virus protein expression was observed by indirect immunofluorescence study using mAbs against NP, F and HN proteins of hPIV-2 (8). The inhibitory effects of the drugs on cell-to-cell spreading of hPIV-2 were analyzed using a recombinant green fluorescence protein (GFP)-expressing hPIV-2 without matrix protein (rhPIV-2ΔM-GFP) (9,13,14). The number of viruses released from infected cells was determined. Cytoskeleton was reported to have an important role in paramyxovirus replication. Actin microfilaments are important in the hPIV-3 life cycle, specifically at the level of viral transport and replication (15). Tubulin also acts as a positive transcription factor for in vitro RNA synthesis by Sendai virus (16). The effects of the drugs on actin microfilaments and microtubules were analyzed using rhodamine phalloidin and anti-tubulin α mAb, respectively.

2. Materials and Methods

2.1. Herbal medicines

Thirteen herbal medicines were chosen because they are effective on common cold and respiratory tract disease. Kakkonto (TJ-001: mainly effective on common cold, fever, headache), Kakkontokasenkyushin’i (TJ-002: sniffle, nasal inflammation), Hangekobukoto (TJ-016: neurosis), Shoseiryuto (TJ-019: nasal inflammation, common cold), Maoto (TJ-027: common cold, rheumatoid arthritis), Bakumondoto (TJ-029: cough, bronchitis), Hochuekkito (TJ-041: tuberculosis, bad appetite, common cold), Goshakusan (TJ-063: gastroenteritis, headache, common cold), Kososan (TJ-070: an early stage of common cold with poor digestion), Chikujountanto (TJ-091: sleeplessness in the convalescent stage of influenza or cold), Gokoto (TJ-095: cough, asthma), Saibokuto (TJ-096: asthma, bronchitis), Ryokankymishingenintu (TJ-119: bronchitis, asthma) were tested for hPIV-2 growth inhibition. The medicines were kind gifts of Tsumura & Co. (Tokyo, Japan) and Akatsuka Pharmacy and Minami Kampo Pharmacy in Tsu City, Mie, Japan.

They were suspended in phosphate-buffered saline (PBS) (100 mg/mL), autoclaved for 15 min, centrifuged at 2,000 rpm for 5 min, and the supernatants were added to the cell culture. The supernatant was stored at -80°C until use.

2.2. Virus and recombinant virus

The virus and the recombinant virus were approved by the relevant biosafety committees of Suzuka University of Medical Science. hPIV-2 (Toshiba strain) was used. rhPIV-2ΔM-GFP was constructed according to the method described previously (9,13,14), and it was shown that it did not produce infectious virus particles without addition of M protein gene in trans (data not shown). The virus titer was determined using Vero cells and the titer was about 1 × 10⁷ TCID₅₀/mL.

2.3. Cell line and cultivation of cells

LLCMK₂ cells (rhesus monkey kidney cell line) were cultured in a flat-bottomed 24-well plate in 1 mL culture medium. Minimum essential medium α (MEMα: FUJIFILM Wako Pure Chemical, Osaka, Japan), supplemented with 2% fetal calf serum (FCS) and 0.1 mg/mL kanamycin (Nacalai Tesque, Kyoto, Japan), was used. The cells were cultured at 37°C in a humidified atmosphere with 5% CO₂. After three days, when the cells became confluent (5 × 10⁴ cells), the medium was changed to MEMα with 0.5% FCS and 0.1 mg/mL kanamycin. The medicines were added to the cells, and the cells were infected with hPIV-2 (3 × 10⁴ TCID₅₀).

2.4. Cytopathogenic assay

Cell fusion was observed at four days post infection under a cell culture microscope.

2.5. RNA preparation, cDNA synthesis, real-time PCR and PCR

RNA was extracted from the cells (2 × 10⁶ cells) cultured in a flat-bottomed 6-well plate using TRIZOL reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's method. cDNA was synthesized with 1 μg RNA using Reverse Tra Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan) and NP gene specific primer (nucleotide number 1661-1679: 5’-CAACATTAAATGGTAATG-3’). Real-time PCR was performed on the ABI PRISM 7700 Sequence Detection System (Thermo Fisher Scientific, Waltham, MA, USA) with the following conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min. The primers were: 5’-CTGCATTGGTCTTCTGCTTT-3’ (sense) and 5’-GCTGAAGGAGCCACCTTTG-3’ (antisense) for the NP gene. PCR was performed on the ABI PRISM 7700 Sequence Detection System (Thermo Fisher Scientific, Waltham, MA, USA) with the following conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min. The primers were: 5’-CTGCATTGGTCTTCTGCTTT-3’ (sense) and 5’-GCTGAAGGAGCCACCTTTG-3’ (antisense) for the NP gene.
The cells were fixed with 3.7% formaldehyde solution in PBS at 37°C for 15 min, washed with PBS, and the cells were further incubated with 0.05% tween20 in PBS at 37°C for 3 min to detect actin and for 15 min to detect microtubules.

2.8. Cell-to-cell spreading of hPIV-2

The drugs were added to the cells, and immediately after the addition, the cells were infected with rhPIV-2∆M-GFP (1 × 10⁴ TCID₅₀), and cultured for four days. They were then fixed with 1.2% formaldehyde solution in PBS at room temperature for 15 min and observed under a fluorescence microscope.

3. Results

3.1. Inhibitory effects of the herbal medicines

Different doses of the supernatants of the thirteen medicines were added to the cell culture, and the cells were infected with hPIV-2, and the cell fusion was observed and a hemadsorption test was carried out at four days post infection. Eight exhibited dose-dependent inhibitory effects and three caused cell toxicity, while two had no inhibitory effect. Table 1 shows the amount (μL) of supernatants of the herbal medicines that had an inhibitory effect on hPIV-2 induced cell fusion and hemadsorption. TJ-001, TJ-002, TJ-019, TJ-029, TJ-041, TJ-091, TJ-095 and TJ-119 had an inhibitory effect on hPIV-2 induced cell fusion and hemadsorption. TJ-027 and TJ-70 had no inhibitory effect. TJ-016, TJ-063 and TJ-096 showed cell toxicity at low concentration. Mainly the medicines which are effective on common cold and bronchitis inhibited hPIV-2 replication. The eight medicines were used in the following experiments.

3.2. Effect of the eight medicines on the release of hPIV-2

The supernatants of virus-infected cells with the medicines were harvested at four days of virus infection; they were diluted, infected to the cells, and the virus titer was determined by the observation of cell fusion and hemadsorption test at four days of culture. Figure 1 shows the titers (averages ± s.e.m. from five independent experiments) of the medicines. TJ-001, TJ-002, TJ-019, TJ-029, TJ-041, TJ-091 and TJ-119 had an inhibitory effect on hPIV-2 induced cell fusion and hemadsorption. TJ-027 and TJ-70 had no inhibitory effect. TJ-016, TJ-063 and TJ-096 showed cell toxicity at low concentration. Mainly the medicines which are effective on common cold and bronchitis inhibited hPIV-2 replication. The eight medicines were used in the following experiments.

3.3. Effect of eight herbal medicines on viral genome RNA and mRNA syntheses

RNA was prepared from the infected cells at four days
post infection, and viral genome RNA was analyzed by real-time PCR and PCR. Viral mRNA was analyzed by PCR.

Figure 2 shows that TJ-001, TJ-002, TJ-019, TJ-091, TJ-095 and TJ-119 almost completely inhibited viral genome RNA synthesis. TJ-019 and TJ-29 largely inhibited. TJ-041 did not inhibit.

Similar results were obtained by PCR (Figure 3). In Figure 3, NP, F and HN protein genes were detected in TJ-041 treated infected cells and they were seen as faint bands in TJ-029 treated cells. The other medicines almost completely inhibited NP, F and HN gene syntheses. These results are similar to those of real-time PCR.

Table 1. Inhibitory effect of herbal medicines and the amounts needed to inhibit virus induced cell fusion and hemadsorption

| Product number | Herbal medicine          | Inhibitory effect | Concentration |
|----------------|--------------------------|-------------------|---------------|
| TJ-001         | Kakkonto                 | +                 | 140 µL/mL     |
| TJ-002         | Kakkontokasenkyushin'i   | +                 | 80 µL/mL      |
| TJ-016         | Hangekobokuto            | -                 | a             |
| TJ-019         | Shoseiryuto              | +                 | 100 µL/mL     |
| TJ-027         | Maoto                    | -                 | b             |
| TJ-029         | Bakumondoto              | +                 | 160 µL/mL     |
| TJ-041         | Hochuekkito              | +                 | 100 µL/mL     |
| TJ-063         | Goshakusan               | a                 |               |
| TJ-070         | Kososan                  | -                 | b             |
| TJ-091         | Chikujoountanto          | +                 | 80 µL/mL      |
| TJ-095         | Gokoto                   | +                 | 80 µL/mL      |
| TJ-096         | Saibokuto                | -                 | a             |
| TJ-119         | Ryokanyakomishingeninto  | +                 | 120 µL/mL     |

a: cell toxicity; b: no inhibitory effect.
Figure 3. Effect of the medicines on viral genome RNA synthesis analyzed by PCR. NP, F and HN genes were detected using specific primers. TJ-001, TJ-002, TJ-019, TJ-091, TJ-095 and TJ-119 inhibited viral genome RNA synthesis. TJ-029 and TJ-041 did not inhibit it. M: size marker.

Figure 4. Effect of the medicines on viral mRNA synthesis analyzed by PCR. RNA was extracted and cDNA was synthesized by oligo(dT) primer. NP, F and HN mRNA were detected using specific primers. TJ-029 and TJ-041 did not inhibit mRNA synthesis. In TJ-095 treated infected cells, NP and HN mRNA were slightly observed, and in TJ-019 and TJ-091, only NP mRNA was faintly detected. M: size marker.

Figure 5. Effect of the medicines on viral protein synthesis. TJ-001 (D-F), TJ-002 (G-I), TJ-029 (M-O) and TJ-091 (S-U) largely inhibited protein synthesis. TJ-119 inhibited F and HN protein synthesis (Z and AA, respectively). In TJ-019 (J-L), TJ-041 (P-R) and TJ-119 (Y) treated infected cells, some positive cells were observed, however, there were no fused giant cells. Arrowheads indicate positive cells. Bar: 100 µm.
in the cytoplasm and on the cell surface. TJ-001 almost completely inhibited the protein syntheses: only a small number of cells were positive in NP, F and HN proteins of infected cells cultured with TJ-001 (Figure 5: D, E and F, respectively). TJ-002 also almost completely inhibited NP, F and HN protein syntheses just the same as TJ-001 treated cells (Figure 5: G, H and I, respectively). TJ-019 also largely inhibited the protein synthesis, but there are some positive cells (arrowheads) especially in F protein (Figure 5: J, K and L: NP, F and HN, respectively). TJ-029 also largely inhibited the protein syntheses (Figure 5: M, N and O: NP, F and HN, respectively). The arrowheads show positive cells. TJ-041 partially inhibited protein syntheses: some positive cells (arrowheads) can be seen (Figure 5: P, Q and R: NP, F, HN, respectively). TJ-091 also largely inhibited protein syntheses (Figure 5: S, T and U: NP, F and HN, respectively). TJ-095 partially inhibited protein syntheses: some positive cells are seen (arrowheads) (Figure 5: V, W and X, respectively). TJ-119 largely inhibited protein syntheses. However, a small number of cells were NP positive (arrowheads in Figure 5Y). Almost no cells were positive on F and HN proteins (Figure 5: Z and AA, F and HN, respectively).

3.5. Effect on the multinucleated giant cell formation

The cells were added with the medicines and immediately after that the cells were infected with rhPIV-2ΔM-GFP and cultured for four days. The cells were fixed with 1.2% formaldehyde and observed with the fluorescence microscope. Figure 6A is a positive control. There are many multinucleated giant cells with strong fluorescence. TJ-001 (Figure 6B) and TJ-002 (Figure 6C) inhibited the giant cell formation: there was a small number of single cells, but no giant cells. TJ-001 and TJ-002 also inhibited the virus release (Figure 1) and virus genome syntheses (Figure 2). TJ-019 (Figure 6D), TJ-029 (Figure 6E) and TJ-041 (Figure 6F) partially inhibited the giant cell formation: there were small sized fused cells with strong fluorescence. TJ-019, TJ-029 and TJ-041 partially inhibited virus release from the cells (Figure 1). TJ-091 also inhibited the giant cell formation (Figure 6G), but a small number of viruses were released (Figure 1). TJ-095 (Figure 6H) inhibited the giant cell formation, but there were some small fused cells (arrowheads in Figure 6H). TJ-095 only partially inhibited the number of released viruses (Figure 1). TJ-119 (Figure 6I) inhibited the giant cell formation: there are some small sized fused cells with weak fluorescence (arrowhead in Figure 6I). TJ-119 inhibited the number of released viruses (Figure 1). The multinucleated giant cell formation, the number of released viruses from the cells, and genome RNA syntheses were in good accordance.

3.6. Effect on actin microfilaments

The medicines were added to the cell culture without virus infection and cultured for four days. F-actin was stained with rhodamine phalloidin. Figure 7A is the positive control: bundles of actin microfilaments were clearly seen. TJ-001 (Figure 7B), TJ-002 (Figure 7C), TJ-019 (Figure 7D) and TJ-095 (Figure 7H) almost completely destroyed the filaments. TJ-041 (Figure 7F) caused partial damage. TJ-029 (Figure 7E), TJ-091 (Figure 7G) and TJ-119 (Figure 7I) almost no effect on them. There are some discrepancies among virus titer, genome RNA synthesis and the number of released virus.
syntheses, and actin filaments, especially in TJ-041. We cannot explain the discrepancy. It was shown that the damage to actin microfilaments caused some inhibitory effects on the release of virus from the cells to culture medium.

3.7. Effect on microtubules

The cells were added with the medicines without virus infection, and cultured for four days. Microtubules were stained with anti-tubulin mAb. Figure 8A is the positive control: microtubule net was seen in the cytoplasm. TJ-001 (Figure 8B) and TJ-002 (Figure 8C) disrupted microtubules. TJ-019 (Figure 8D), TJ-041 (Figure 8F), TJ-095 (Figure 8H), and TJ-119 (Figure 8I) caused a little damage in microtubules. TJ-029 (Figure 8E) and TJ-091 (Figure 8G) had almost no effect on microtubules. Microtubules are also important for virus replication, so one of the causes of virus replication inhibition had some relation with the disruption of microtubules.

4. Discussion

Thirteen herbal medicines, which are effective on common cold and respiratory diseases, were tested against hPIV-2 replication in vitro. Eight out of thirteen medicines had inhibitory effects on hPIV-2 replication. The effects on genome RNA synthesis, viral mRNA synthesis, protein expression, multi-nucleated giant cell formation and cytoskeleton (actin microfilaments and microtubules) were analyzed.

Kakkonto (TJ-001), Kakkontokasenkyushin’i (TJ-002) and Ryokankyoymishingeninto (TJ-119) had strong inhibitory effects on hPIV-2 replication. They inhibited virus genome RNA synthesis, virus mRNA synthesis, virus-induced multinucleated giant cell formation and virus protein synthesis, though in TJ-119 treated infected cells, a small number of cells were NP positive. TJ-001, TJ-002 almost completely inhibited virus induced multinucleated giant cell formation. In Shoseiryuto (TJ-019), Bakumondoto (TJ-029) and Hochuekkito (TJ-041) treated infected cells, small sized giant cells were observed, indicating that these three medicines could not fully inhibit the transmission of virus to the nascent cells. Chikujontanto (TJ-091), Gokoto (TJ-095) and TJ-119 inhibited giant cell formation, but some non-fused fluorescent cells were observed. In TJ-019, TJ-029 and TJ-041 treated infected cells, F protein expression was not fully inhibited. This may be one of the reasons for the appearance of small sized fused cells. In TJ-095 added infected cells, though the expression of NP, F and HN proteins were observed, there were almost no fused cells. In TJ-019, TJ-029 and TJ-041 treated infected cells, F protein was expressed as small dots on the cell surface. However, in TJ-095 treated infected cells, F protein was expressed mainly in the cytoplasm, not in the cell membrane, resulting in the inhibition of cell fusion. TJ-001 and TJ-002 caused damage to actin microfilaments and microtubules, but TJ-119 did not cause damage in actin microfilaments or microtubules. One of the reasons for inhibition by TJ-001 and TJ-002 was damage to actin microfilaments and microtubules, suggesting that the inhibitory mechanisms by TJ-119 may be different from those of TJ-001 and TJ-002.

Many investigations show that the medicines tested in this study inhibit various virus replications by different mechanisms. For instance, Kakkonto inhibits human respiratory syncytial virus infection by preventing viral attachment and internalization to the host cells (17). Kakkonto also possesses inhibitory activity against influenza virus polymerase acidic protein endonuclease (18). Hochuekkito binds to influenza virus particles and forms complexes and can obstruct the entry of the virus into cells (12). Hochuekkito also inhibits rhinovirus infection in vitro, partly by inhibiting the expression of its receptor, ICAM-1 (19). Shoseiryuto inhibits human cytomegalovirus replication in vitro by inhibiting viral DNA replication (20). Shoseiryuto is also effective against human respiratory syncytial virus infection on airway epithelia by preventing viral attachment and internalization to the host cells and by stimulating interferon secretion (21). Maoto has clinical efficacy for seasonal influenza, and it has equivalent clinical and virological efficacy to oseltamivir and zanamivir (22). It inhibits uncoating of influenza virus by inhibiting acidification and blocks influenza virus entry to cytoplasm (II).

One of the questions is which components of the medicines are effective on virus replication.
Glycyrrhizin is the effective component of *Glycyrrhiza radix*, and has an inhibitory efficacy for various virus replications *in vitro*, such as H5N1 influenza A virus (23), cytomegalovirus (20), rhinovirus (19) and human respiratory syncytial virus (24). Most herbal medicines which are effective on common cold and respiratory diseases contain extract of *Glycyrrhiza radix*. The medicines tested in this study contain *Glycyrrhiza radix* as an ingredient, except for Hangekobokuto (TJ-016). Glycyrrhizin also inhibits hPIV-2 replication *in vitro* (25), but effective concentration is much higher than that in these medicines and there is a significant difference in inhibitory efficacy between the medicines (Table 1). Therefore, glycyrrhizin may have only a small contribution to inhibit hPIV-2 replication in the medicines.

Both Kakkonto (18) and Maoto (11) have inhibitory effects on influenza virus replication. Maoto has inhibitory efficacy in influenza virus replication and its efficacy is partly derived from *Glycyrrhiza radix* (26). Kakkonto (TJ-001) and Kakkontokasenkyushin’i (TJ-002) showed strong inhibitory effects on hPIV-2 replication (Figure 1), although Maoto (TJ-027) did not (Table 1). Three crude drugs, *Ephedrae herba*, *Cinnamomi cortex* and *Glycyrrhizae radix*, are common ingredients to these three medicines (Table 2). Therefore, the inhibitory mechanism for hPIV-2 replication by herbal medicines may be different from that for influenza virus. Four crude drugs, *Puerariae radix*, *Ziziphi fructus*, *Paeoniae radix* and *Zingiberis rhizoma*, are contained in Kakkonto and Kakkontokasenkyushin’i, but not in Maoto (Table 2). The results in this study suggest that one of the four crude drugs, or combination of two, three or all of them, is effective to inhibit hPIV-2 replication.

*Ryokankymishingeninto* (TJ-119) also showed a strong inhibitory effect on hPIV-2 replication (Figure 1). It contains *Glycyrrhiza radix* as an ingredient, but not *Puerariae radix*, *Ziziphi fructus*, *Paeoniae radix* or *Zingiberis rhizoma* (Table 2), which are contained in Kakkonto and Kakkontokasenkyushin’i. Therefore, the inhibitory mechanism on hPIV-2 replication by *Ryokankymishingeninto* may be different from that of Kakkonto and Kakkontokasenkyushin’i.

The inhibitory mechanism for hPIV-2 replication by herbal medicines may be multiple. The medicines have many components, and some can inhibit virus genome synthesis, mRNA synthesis and/or protein synthesis, and at the same time, destroy actin microfilaments and/or microtubules. In the present study, the medicines were suspended in PBS, autoclaved, and the supernatant was added to the cell culture, so some insoluble materials and heat unstable substances that may have inhibitory effects might be missing.

The next aim is to analyze and to extract the compounds that can inhibit not only parainfluenza virus but also respiratory syncytial virus, measles virus, mumps virus and metapneumovirus.

**Funding:** None.

**Conflict of Interest:** The authors have no conflicts of interest to disclose.

**References**

1. Lamb RA, Parks GP. Paramyxoviridae: The viruses and their Replication. In: Fields Virology, 5th edn. (Kniep DM, Howley PM, eds.). Lippincott Williams and Wilkins, Philadelphia, USA, 2008; pp. 1449-1496.
2. Yuasa T, Bando H, Kawano M, Tsurudome M, Nishio M, Kondo K, Komada H, Ito Y. Sequence analysis of the 3’ genome end and NP gene of human parainfluenza type 2 virus; sequence variation of the gene starting signal and the conserved 3’ end. Virology. 1990; 179:777-784.
3. Ohgimoto S, Bando H, Kawano M, Okamoto K, Kondo K, Tsurudome M, Nishio M, Ito Y. Sequence analysis of P gene of human parainfluenza type 2 virus; P and cystein-rich proteins are translated by two mRNAs that differ by two non-templated G residues. Virology. 1990; 177:116-123.
4. Kawano M, Bando H, Ohgimoto S, Okamoto K, Kondo K, Tsurudome M, Nishio M, Ito Y. Complete nucleotide sequence of the matrix gene of human parainfluenza type 2 virus and expression of the M protein in bacteria. Virology. 1990; 179:857-861.
5. Kawano M, Bando H, Ohgimoto S, Okamoto K, Kondo K, Tsurudome M, Nishio M, Ito Y. Sequence of the fusion protein gene of human parainfluenza type 2 virus and its 3’ intergenic region: lack of small hydrophobic (SH) gene. Virology. 1990; 178:289-292.
M. Komada H, Nishio M, Ito Y. Sequence determination of the hemagglutinin-neuraminidase (HN) gene of human parainfluenza type 2 virus and the construction of a phylogenetic tree for HN proteins of all the paramyxoviruses that are infectious to humans. Virology. 1990; 174:308-313.

7. Kawano M, Okamoto K, Bando H, Kondo K, Tsurudome M, Komada H, Nishio M, Ito Y. Characterizations of the human parainfluenza type 2 virus gene encoding the L protein and the intergenic sequences. Nucleic Acids Res. 1991; 19:2739-2746.

8. Tsurudome M, Nishio M, Komada H, Bando H, Ito Y. Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies. Virology. 1989; 171:38-48.

9. Kawano M, Kaito M, Kozuka Y, Komada H, Noda N, Namba K, Tsurudome M, Ito M, Nishio M, Ito Y. Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology. 2001; 284:99-112.

10. Nagai T, Urata T, Yamada H. In vivo anti-influenza virus activity of kampo (Japanese herbal) medicine "Sho-seiryuto" – effects on aged mice, against subtypes of a viruses and B virus, and therapeutic effect. Immunophamacol Immunotoxicol. 1996; 18:193-208.

11. Masui S, Nabheshima S, Ajsika K, Yamauuchi K, Itoh R, Ishii K, Soejima T, Hiromatsu K. Maoto, a traditional Japanese herbal medicine, inhibits uncoating of influenza virus. Evid Based Complement Alternat Med. 2017; 2017:102065.

12. Dan K, Takenashi K, Akiyoshi H, Munakata K, Hasegawa H, Ogawa K, Watanabe K. Mechanism of action of the anti-influenza virus active kampo (traditional Japanese herbal) medicine, Hochuekkito. Pharmacology. 2018; 101:148-155.

13. Uematsu J, Koyama A, Takano S, Ura Y, Tanemura M, Kihira S, Yamamoto H, Kawano M, Tsurudome M, O’Brien M, Komada H. Legume lectins inhibit human parainfluenza virus type 2 infection by interfering with the entry. Viruses. 2012; 4:1104-1115.

14. Kitagawa H, Kawano M, Yamanaka K, Kakeda M, Tsuda K, Inada H, Yoneda M, Sakaguchi T, Nigi A, Nishimura K, Komada H, Tsurudome M, Yasutomi Y, Nosaka T, Mizutani H. Intranasally administered antigen 85B gene vaccine in non-replicating human parainfluenza type 2 virus and its effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. Plos One. 2011; 6:e19705.

15. Chang JS, Yeh CF, Wang KC, Shieh DE, Yen MH, Chiang LC. Xiao-Qing-Long-Tang (Sho-seiryu-to) inhibited cytopathic effect of human respiratory syncytial virus in cell lines of human respiratory tract. J Ethnopharmacol. 2013; 147:481-487.

16. Nakayama T, Yamaguchi N, Matsuno H, Eizuru Y. In vitro anti-cytomegalovirus activity of kampo (Japanese herbal) medicine. Evid Based Complement Alternat Med. 2004; 1:285-289.

17. Chang JS, Wang KC, Shieh DE, Hsu FF, Chiang LC. Ge-Gen-Tang has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J Ethnopharmacol. 2012; 139:305-310.

18. Shirayama R, Shoji M, Srisilaiajaroen N, Hiramatsu H, Suzuki Y, Kuzuhara T. Inhibition of PA endonuclease activity of influenza virus RNA polymerase by Kampo medicines. Drug Discov Ther. 2016; 10:109-113.

19. Yamada M, Sasaki T, Yasuda H, Inoue D, Suzuki T, Asada M, Yoshihisa M, Seki T, Iwasaki K, Nishimura H, Nakayama K. Hochu-ekki-to inhibits rhinovirus infection in human tracheal epithelial cells. Br J Pharmacol. 2007; 150:702-710.

20. Murayama T, Yamaguchi N, Matsuno H, Eizuru Y. In vitro anti-cytomegalovirus activity of kampo (Japanese herbal) medicine. Evid Based Complement Alternat Med. 2004; 1:285-289.

21. Nakayama T, Yamaguchi N, Matsuno H, Eizuru Y. In vitro anti-cytomegalovirus activity of kampo (Japanese herbal) medicine. Evid Based Complement Alternat Med. 2004; 1:285-289.

22. Chang JS, Yeh CF, Wang KC, Shieh DE, Yen MH, Chiang LC. Xiao-Qing-Long-Tang (Sho-seiryu-to) inhibited cytopathic effect of human respiratory syncytial virus in cell lines of human respiratory tract. J Ethnopharmacol. 2013; 147:481-487.

23. Nakayama T, Yamaguchi N, Matsuno H, Eizuru Y. In vitro anti-cytomegalovirus activity of kampo (Japanese herbal) medicine. Evid Based Complement Alternat Med. 2004; 1:285-289.

24. Chang JS, Yeh CF, Wang KC, Shieh DE, Yen MH, Chiang LC. Xiao-Qing-Long-Tang (Sho-seiryu-to) inhibited cytopathic effect of human respiratory syncytial virus in cell lines of human respiratory tract. J Ethnopharmacol. 2013; 147:481-487.

25. Nakayama T, Yamaguchi N, Matsuno H, Eizuru Y. In vitro anti-cytomegalovirus activity of kampo (Japanese herbal) medicine. Evid Based Complement Alternat Med. 2004; 1:285-289.

26. Nakayama T, Yamaguchi N, Matsuno H, Eizuru Y. In vitro anti-cytomegalovirus activity of kampo (Japanese herbal) medicine. Evid Based Complement Alternat Med. 2004; 1:285-289.